Clinical Publications

November 1, 2022

Circulating Tumor HPV-DNA Kinetics in p16+ Oropharyngeal Cancer Patients Undergoing Adaptive Radiation De-Escalation Based on Mid-Treatment Nodal Response

November 1, 2022

ctHPVDNA and Recurrence Risk in MC1675, a Secondary Analysis of a Phase III Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) vs. Standard Adjuvant Treatment for HPV Associated Oropharyngeal Squamous Cell Carcinoma

October 27, 2022

Association of Pretreatment Circulating Tumor Tissue–Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer

June 3, 2022

Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002

May 16, 2022

Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma

March 28, 2022

Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma

March 9, 2022

Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer

March 2022

The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation☆

February 25, 2022

Patterns of Failure and Cost Analysis for Integrating a Novel Tumor HPV DNA Assay Into HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+OPSCC) Recurrence Surveillance

February 11, 2022

Detectable Postoperative Circulating Tumor Human Papillomavirus (HPV) DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma

January 25, 2022

Estimated Cost of Circulating Tumor DNA for Posttreatment Surveillance of Human Papillomavirus–Associated Oropharyngeal Cancer

November 1, 2021

Detection of Plasma Circulating Tumor-Tissue Modified HPV DNA Following Trans-Oral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma

July 24, 2021

Cost-Effectiveness Of Circulating Tumor HPV DNA For The Surveillance Of Cancer Recurrence In HPV-Associated Oropharyngeal Cancer

May 28, 2021

Evaluating a clinically validated circulating tumor HPV DNA assay in saliva as a proximal biomarker in HPV+ oropharyngeal squamous cell carcinoma.

May 26, 2021

Circulating tumor-tissue modified HPV DNA analysis for molecular disease monitoring after chemoradiation for anal squamous cell carcinoma: a case report

November 1, 2020

Pre-Treatment Circulating Tumor Human Papillomavirus (HPV) DNA and Recurrence Risk in HPV Associated Malignancy: Oropharyngeal, Anal Canal, and Cervical Cancer

April 1, 2020

Quantity of ctDNA by Risk Category for Post-Operative Patients with HPV Associated Oropharyngeal Squamous Cell Carcinoma

February 04, 2020

Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer

November 1, 2019

Detectable HPV ctDNA in Post-Operative Oropharyngeal Squamous Cell Carcinoma Patients is Associated With Progression

August 1, 2019

Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer